Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald

Arvinas (NASDAQ:ARVN - Get Free Report)'s stock had its "overweight" rating restated by analysts at Cantor Fitzgerald in a report issued on Friday,Benzinga reports.

Other research analysts have also issued research reports about the stock. BMO Capital Markets reduced their price objective on shares of Arvinas from $90.00 to $88.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 20th. HC Wainwright restated a "buy" rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Stephens initiated coverage on shares of Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective on the stock. Oppenheimer lowered their target price on shares of Arvinas from $50.00 to $40.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Finally, Barclays lowered their target price on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Arvinas presently has an average rating of "Moderate Buy" and a consensus target price of $61.45.

Arvinas Price Performance

Shares of NASDAQ ARVN traded down $1.29 during mid-day trading on Friday, hitting $17.68. The company's stock had a trading volume of 1,863,711 shares, compared to its average volume of 892,133. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.79 and a beta of 1.88. Arvinas has a one year low of $16.61 and a one year high of $53.08. The company's fifty day simple moving average is $19.46 and its 200-day simple moving average is $23.44.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same quarter in the prior year, the business posted ($2.53) earnings per share. On average, sell-side analysts predict that Arvinas will post -3.22 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Handelsbanken Fonder AB raised its holdings in Arvinas by 17.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 19,525 shares of the company's stock valued at $481,000 after buying an additional 2,900 shares during the last quarter. Exchange Traded Concepts LLC grew its position in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after purchasing an additional 1,798 shares during the period. nVerses Capital LLC acquired a new stake in Arvinas in the 3rd quarter valued at $39,000. Assenagon Asset Management S.A. acquired a new stake in Arvinas in the 3rd quarter valued at $3,442,000. Finally, E. Ohman J or Asset Management AB lifted its stake in Arvinas by 20.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 29,830 shares of the company's stock valued at $735,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.